GlassScriptPhysician profile
Amanda L Bachman
NPI 1396950788
$8,099.77
in general payments reported to CMS, 2019-2025
24 companies · $1,652 in 2025
The $1,652 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,082 · 2020: $832 · 2021: $918 · 2022: $1,085 · 2023: $1,249 · 2024: $1,281 · 2025: $1,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,182.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,600.76 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Allergan, INC. | $1,164.85 | 2019-2022 | |
| Alcon Vision LLC | $1,056.95 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Sun Pharmaceutical Industries INC. | $1,038.96 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $486.02 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $395.13 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $323.07 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $294.97 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Optos, INC. | $240.04 | 2020 | |
| Eyevance Pharmaceuticals LLC | $198.26 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $170.84 | 2021-2023 | Eylea |
| Biotissue Holdings INC. | $142.71 | 2019-2024 | |
| Harrow Eye, LLC | $141.45 | 2024-2025 | Vevye |
| Glaukos Corporation | $139.39 | 2021-2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa, Idose |
| Rxsight INC | $132.08 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $112.64 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $110.12 | 2019-2022 | |
| Sight Sciences, INC. | $99.18 | 2019-2022 | |
| Shire North American Group INC | $85.37 | 2019 | |
| Ivantis, INC | $44.56 | 2019 | |
| Horizon Therapeutics Plc | $37.57 | 2023 | Tepezza |
| Mallinckrodt Enterprises LLC | $34.87 | 2019 | |
| Dompe US, INC. | $31.82 | 2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $18.16 | 2023 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Bachman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.